Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Andrea CorbaciogluKonstanze Döhner

Abstract

To evaluate the prognostic impact of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) expressing the CBFB-MYH11 fusion transcript. Quantitative reverse transcriptase polymerase chain reaction (PCR) was performed on 684 bone marrow (BM; n = 331) and/or peripheral blood (PB; n = 353) samples (median, 13 samples per patient) from 53 younger adult (16 to 60 years old) patients with AML treated in prospective German-Austrian AML Study Group treatment trials. Samples were obtained at diagnosis (BM, n = 45; PB, n = 48), during treatment course (BM, n = 153; PB, n = 122), and at follow-up (BM, n = 133; PB, n = 183). To evaluate the applicability of PB for MRD detection, 198 paired BM and PB samples obtained at identical time points were analyzed. The following three clinically relevant checkpoints were identified during consolidation and early follow-up that predicted relapse: achievement of PCR negativity in at least one BM sample during consolidation therapy (2-year relapse-free survival [RFS], 79% v 54% for PCR positivity; P = .035); achievement of PCR negativity in at least two BM or PB samples during consolidation therapy and early follow-up (< or = 3 months; 2-year RFS, P = .001; overall survival, P = ...Continue Reading

References

Dec 4, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen KrauterGerhard Heil
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
Aug 12, 2008·Seminars in Oncology·Sylvie D FreemanDavid Grimwade
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetUNKNOWN Core Binding Factor Acute Myeloid Leukemia (CBF AML) intergroup

❮ Previous
Next ❯

Citations

Oct 1, 2011·Current Treatment Options in Oncology·Rob SellarHillard M Lazarus
Apr 9, 2013·Current Hematologic Malignancy Reports·Karen-Sue B Carlson, Monica L Guzman
Jul 14, 2012·International Journal of Hematology·Andrea Kühnl, David Grimwade
Feb 9, 2012·Current Opinion in Hematology·Courtney D DiNardo, Selina M Luger
Jan 19, 2013·Current Opinion in Hematology·Ryan J MattisonHillard M Lazarus
Feb 6, 2013·Current Opinion in Hematology·Elaine Coustan-Smith, Dario Campana
Dec 10, 2013·Hematology·Peter Paschka, Konstanze Döhner
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana
May 23, 2015·Current Hematologic Malignancy Reports·Sabine KayserRichard F Schlenk
Mar 20, 2015·Der Internist·K DöhnerH Döhner
Nov 3, 2016·Bone Marrow Transplantation·A M BrunnerY B Chen
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Jun 24, 2017·Leukemia·V I GaidzikUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
Nov 4, 2017·Current Hematologic Malignancy Reports·Yi Zhou, Brent L Wood
Oct 7, 2018·Cancer·Hagop M KantarjianEmil J Freireich
Jan 16, 2013·The Korean Journal of Hematology·Dario Campana, Elaine Coustan-Smith
Mar 29, 2019·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mats Ehinger, Louise Pettersson
Feb 14, 2019·Annals of Hematology·Ho-Jin ShinUNKNOWN Korean Society of Hematology AML/MDS Working Party
Sep 21, 2011·Expert Review of Anticancer Therapy·Carmelo RizzariValentino Conter
Nov 1, 2012·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Charlotta AnderssonAihong Li
Jan 13, 2018·Journal of Cellular and Molecular Medicine·Bryan BrindaHeiko Konig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.